Abstract
In the last few decades, our knowledge of cannabinoid structure–activity relationships (SARs) has increased dramatically. Computational methods have allowed us to compare active and inactive ligands for steric, electronic, and conformational similarities and dissimilarities. Knowing that there are specific G-protein-coupled cannabinoid receptors with which cannabinoids interact, we increasingly interpret changes in structure to specific alterations in ligand–receptor interaction. With additional knowledge of the CB1 and CB2 receptors’ sequence, the consequences of mutations and chimeric constructs of the receptor, and the development of rhodopsin-based homology models of the cannabinoid receptors, we continue to gain insight into the interaction of cannabinoids with their receptors. Finally, our emerging appreciation for cannabinoid homo- and heterodimerization/oligomerization provides for further understanding of ligand–receptor interactions, the interaction of receptors with each other, and the interaction of G-protein-coupled receptors with their signal transduction components and other molecules affecting each receptor’s dynamics. In the following review, we have attempted to characterize the emerging SARs of an important class of cannabinoid ligands: the CB1 receptor antagonists and inverse agonists. This class of compounds is showing therapeutic potential for a variety of indications, and is therefore of interest for both basic research and pharmaceutical development. Throughout this work, we have used molecular modeling, particularly quenched molecular dynamics, to illustrate particular structural modifications that have been reported for CB1 antagonists, their conformational properties, and the potential implications for receptor interaction. In this way, we hope this review serves to further guide medicinal chemists in their understanding of CB1 receptor antagonist SAR and the design of new analogs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–13.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5.
Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–9.
Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA. 1997;94:2238–42.
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–7.
Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions. Br J Pharmacol. 2003;138:544–53.
Martin RS, Secchi RL, Sung E, et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Effects of SR 141716A on rat models of psychosis. Psychopharmacology (Berlin, Germany). 2003;165:128–35.
Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:355–60.
BrodKin J, Moerschbaecher JM. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J Pharmacol Exp Ther. 1997;282:1526–32.
Nakamura-Palacios EM, Winsauer PJ, Moerschbaecher JM. Effects of the cannabinoid ligand SR 141716A alone or in combination with Δ9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. Behav Pharmacol. 2000;11:377–86.
Mansbach RS, Rovetti CC, Winston EN, Lowe JA, 3rd. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 1996;124:315–22.
Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol. 1994;55:107–15.
Terranova JP, Storme JJ, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996;126:165–72.
Lichtman AH. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol. 2000;404:175–9.
Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, et al. Cannabinoid CB1 antagonists possess Antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental Parkinsonism. Neurobiol Dis. 2005;18:591–601.
Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 2001;156:79–85.
Braida D, Iosue S, Pegorini S, Sala M. 3,4-Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res. 2005;51:177–82.
De Vries TJ, de Vries W, Janssen MCW, Schoffelmeer ANM. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res. 2005;161:164–8.
Economidou D, Mattioli L, Cifani C, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 2006;183:394–403.
Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W. Cannabinoid CB1 antagonist SR141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology. 2005;48:1097–104.
Freedland CS, Sharpe AL, Samson HH, Porrino LJ. Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res. 2001;25:277–82.
Navarro M, Carrera MRA, del Arco I, Trigo JM, Koob GF, Rodriguez de Fonseca F. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur J Pharmacol. 2004;501:235–7.
Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther. 2003;306:93–102.
Mas-Nieto M, Pommier B, Tzavara ET, et al. Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol. 2001;132:1809–16.
De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer ANM. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berlin, Germany) 2003;168:164–9.
De Vries TJ, Shaham Y, Homberg JR, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2001;7:1151–4.
Arnone Ml, Maruani J, Chaperon Fdr, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104–106.
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998;63:PL113–PL7.
Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–5.
Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240–4.
Antel J, Gregory P-C, Krause G, inventors; (Solvay Pharmaceuticals GmbH, Germany). Assignee. Combination treatment of obesity involving selective CB1 antagonists and lipase inhibitors. Application: WO patent 2004-EP52643 2005039579 2005 20041022.
Piomelli D, De Fonseca FR, Fu J, Gaetani S, inventors; (The Regents of the University of California, USA). Assignee. Combination therapy using CB1 cannabinoid antagonists with PPARa agonists or other compounds for controlling appetites. Application: WO patent 2003-US25760 2004034968 2004 20030815.
Weber E, Cowley MA, inventors; (Orexigen Therapeutics, Inc., USA). Assignee. Compositions containing an opioid antagonist and a cannabinoid receptor antagonist for affecting weight loss. Application: WO patent 2005-US13193 2005107806 2005 20050419.
Murineddu G, Ruiu S, Loriga G, et al. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo [6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J Med Chem. 2005;48:7351–62.
Murineddu G, Ruiu S, Mussinu JM, et al. Tricyclic pyrazoles. Part 2: synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. Bioorg Med Chem. 2005;13:3309–20.
Stoit AR, Lange JH, Hartog AP, et al. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull (Tokyo). 2002;50:1109–13.
Ruiu S, Pinna GA, Marchese G, et al. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther. 2003;306:363–70.
Zhang Y, Burgess JP, Brakeen M, et al. Conformationally-constrained analogs of SR141716. In: Presentation at the Annual Meeting of the International Cannabinoid Research Society. Budapest Hungary; 2006.
Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav. 2002;74:31–40.
Francisco MEY, Burgess JP, George C, et al. Structure elucidation of a novel ring-constrained biaryl pyrazole CB1 cannabinoid receptor antagonist. Magn Reson Chem. 2003;41:265–8.
Hurst DP, Lynch DL, Barnett-Norris J, et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) Interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol. 2002;62:1274–87.
Carpino PA, Griffith DA, Sakya S, et al. New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg Med Chem Lett. 2006;16:731–6.
Lange JH, Kruse CG. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today. 2005;10:693–702.
Lan R, Liu Q, Fan P, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem. 1999;42:769–76.
Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, Martin BR. Novel pyrazole cannabinoids: insights into CB1 receptor recognition and activation. J Pharmacol Exp Ther. 2001;296:1013–22.
Thomas BF, Francisco ME, Seltzman HH, et al. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem. 2005;13:5463–74.
Dow RL, Hammond M, inventors; (Pfizer Products Inc., USA). Assignee. Preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists. Application: WO patent 2003-IB5835 2004052864 2004 20031203.
Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284:644–50.
Dyck B, Goodfellow VS, Phillips T, et al. Potent imidazole and triazole CB1 receptor antagonists related to SR141716. Bioorg Med Chem Lett. 2004;14:1151–4.
Jagerovic N, Hernandez-Folgado L, Alkorta I, et al. Structural–activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur J Med Chem. 2006;41:114.
Lange JH, van Stuivenberg HH, Coolen HK, et al. Bioisosteric replacements of the pyrazole moiety of Rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem. 2005;48:1823–38.
Jagerovic N, Hernandez-Folgado L, Alkorta I, et al. Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem. 2004;47:2939–42.
Plummer CW, Finke PE, Mills SG, et al. Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorg Med Chem Lett. 2005;15:1441.
Berggren AIK, Bostrom SJ, Cheng L, et al., inventors; (Astrazeneca Ab, Swed.; Astrazeneca Uk Limited). Assignee. Preparation of 1,5-diaryl-pyrrole-3-carboxamide derivatives as cannabinoid receptor modulators. Application: WO patent 2003-GB5569 2004058249 2004 20031218.
Smith RA, Kluender HCE, Su N, Lavoie RC, Fan J, inventors; (Bayer Pharmaceuticals Corporation, USA). Assignee. Preparation and use of pyrrolecarboxamides and pyrrolecarbohydrazides for treating obesity. Application: WO patent 2002-US30543 2003027069 2003 20020924.
Kanyonyo M, Govaerts SJ, Hermans E, Poupaert JH, Lambert DM. 3-Alkyl-(5,5′-diphenyl)imidazolidineiones as new cannabinoid receptor ligands. Bioorg Med Chem Lett. 1999;9:2233–6.
Ooms F, Wouters J, Oscari O, et al. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. J Med Chem. 2002;45:1748–56.
Govaerts SJ, Muccioli GG, Hermans E, Lambert DM. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. Eur J Pharmacol. 2004;495:43–53.
Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem. 2005;12:1361–94.
Muccioli GG, Wouters J, Charlier C, et al. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: Characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. J Med Chem. 2006;49:872–82.
Lange JH, Coolen HK, van Stuivenberg HH, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem. 2004;47:627–43.
Meurer LC, Finke PE, Mills SG, et al. Synthesis and SAR of 5,6-diarylpyridines as Shuman CB1 inverse agonists. Bioorg Med Chem Lett. 2005;15:645.
Cheng L, inventor (Astrazeneca AB, Swed.). Assignee. Preparation of 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and 2-sulfonamide derivatives as cannabinoid receptor 1 (CB1) modulators. Application: WO patent 2004-SE970 2004111034 2004 20040616.
Davidson JEP, Dawson CE, Harrison K, et al., inventors; (Vernalis Research Limited, UK). Assignee. Preparation of azetidinecarboxamide derivatives for the treatment of CB1 receptor-mediated disorders. Application: WO patent 2004-GB1831 2004096763 2004 20040429.
Alanine A, Beleicher K, Guba W, et al., inventors; (F.Hoffmann-La Roche AG, Switz.; Hoffmann La Roche). Assignee. Preparation of benzodioxoles as CB1 receptor modulators for potential therapeutic use against obesity and other disorders. Application: WO patent 2003-EP7890 2004013120 2004 20030718.
Castonguay LA, Hagmann WK, Lin LS, Shah SK, inventors; (Merck & Co., Inc., USA). Assignee. Preparation of substituted bicyclic arylamide cannabinoid-1 receptor antagonists and/or inverse agonists for use as psychotropic drugs. Application: WO patent 2003-US10740 2003086288 2003 20030408.
Nettekoven MH, Roever S, inventors; (Germany). Assignee. Preparation of benzothiazole amide derivatives as cannabinoid (CB1) receptor ligands. Application: US patent 2004-871952 2004266845 2004 20040618.
Razdan RK, Mahadevan A. Recent advances in the synthesis of endocannabinoid related ligands. Chem Phys Lipids. 2002;121:21.
Di Marzo V, Bisogno T, Melck D, et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 1998;436:449.
Acknowledgments
The authors would like to acknowledge the financial support received from the National Institute on Drug Abuse (R01 DA019217).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zhang, Y., Seltzman, H.H., Brackeen, M., Thomas, B.F. (2009). Structure–Activity Relationships and Conformational Freedom of CB1 Receptor Antagonists and Inverse Agonists. In: Reggio, P.H. (eds) The Cannabinoid Receptors. The Receptors. Humana Press. https://doi.org/10.1007/978-1-59745-503-9_4
Download citation
DOI: https://doi.org/10.1007/978-1-59745-503-9_4
Publisher Name: Humana Press
Print ISBN: 978-1-58829-712-9
Online ISBN: 978-1-59745-503-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)